KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients

British Journal of Cancer

Volumn 108, Issue 1, 2013, Pages 115-120

  Basso, M ^a   Strippoli, A ^a   Orlandi, A ^a   Martini, M ^a   Calegari, M A ^a   Schinzari, G ^a   Di Salvatore, M ^a   Cenci, T ^a   Cassano, A ^a   Larocca, L M ^a   Barone, C ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

EGFR; ERCC 1; KRAS; oxaliplatin

Indexed keywords

BEVACIZUMAB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; MESSENGER RNA; OXALIPLATIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SURVIVAL TIME;

COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84872610995     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.526     Document Type: Article

References (26)

1. Altaha R, Liang X, Yu JJ, Reed E (2004) Excision repair cross-complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14: 959-970.
2. Balin-Gauthier D, Delord JP, Pillaire MJ, Rochaix P, Hoffman JS, Bugat R, Cazaux C, Canal P, Allal BC (2008) Cetuximab potentiates oxaliplatin-induced cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 98: 120-128.
3. Benhar M, Engelberger D, Levitzki A (2002) Cisplatin-induced activation of the EGFR receptor. Oncogene 21: 8723-8731.
4. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin and oxaliplatin with or without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671.
5. Breen D, Barlesi F (2008) The place of excision repair cross complementation 1 (ERCC-1) in surgically treated non-small cell lung cancer. Eur J Cardiothorax Surg 33: 805-811.
6. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D (2000) ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 89: 453-457.
7. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small cell lung cancer. J Clin Oncol 25: 2747-2754.
8. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Eng J Med 351: 337-345.
9. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Bł-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31): 4697-4705.
10. Ferry KV, Hamilton TC, Johnson SW (2000) Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 60: 1305-1313.
11. Hanawalt PC (2002) Subpathways of nucleotide excision repair and their regulation. Oncogene 21: 8949-8956.
12. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutation and benefit from cetuximab in advanced colorectal cancer. N Eng J Med 359: 1757-1765.
13. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E (2000) Association between the level of ERCC1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20: 645-652.
14. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP. on behalf of the MRC Trial Investigators (2011) Addition of cetuximab to oxaliplatin based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377: 2103-2114.
15. Orlandi A, Di Salvatore M, Basso M, Bagalà C, Strippoli A, Plastino F, Dadduzio E, Di Lascio S, Quirino M, Cassano A, Astone A, Barone C (2012) ERCC1, KRAS mutation and oxaliplatin sensitivity: old dogs and new tricks. J Clin Oncol 30(Suppl 4) abstract 489.
16. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28(31): 4706-4713.
17. Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24: 331-344.
18. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27: 5931-5937.
19. Rosell R, Mendez P, Isla D, Taron M (2007) Platinum resistance related to a functional NER pathway. J Thorax Oncol 2: 1063-1066.
20. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ. FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomized controlled trial. Lancet 370: 143-152.
21. Shellard SA, Fichtinger-Schepman AM, Lazo JS, Hill BT (1993) Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 4: 491-500.
22. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 9(23): 4298-4304.
23. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Halfdan S, Pyrrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen, Erdal AB, Dajani O, Dahl O, Christoffersen T (2012) Phase III trial of Cetuximab with continuous or intermittent fluorouracil, leucovorin and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer. The NORDIC-VII study. J Clin Oncol 30(15): 1755-1762.
24. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Eng J Med 360: 1408-1417.
25. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664.
26. Yang G, Curley D, Bosenberg MW, Tsao H (2007) Loss of Xeroderma Pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-deficient mice. Cancer Res 67(12): 5649-5657.